Reducing pancreatitis risk in patients with hypertriglyceridemia

Affiliations

¹ Research Coordinator in the Faculty of Pharmaceutical Sciences at the University of British Columbia in Vancouver.
² Professor in the Department of Family Medicine at the University of Alberta in Edmonton.
³ Assistant Professor at the University of British Columbia and Clinical Pharmacy Specialist at St Paul's Hospital in Vancouver.

Blair J MacDonald et al. Can Fam Physician. 2023 Dec.

. 2023 Dec;69(12):849.

doi: 10.46747/cfp.6912849.

¹ Research Coordinator in the Faculty of Pharmaceutical Sciences at the University of British Columbia in Vancouver.
² Professor in the Department of Family Medicine at the University of Alberta in Edmonton.
³ Assistant Professor at the University of British Columbia and Clinical Pharmacy Specialist at St Paul's Hospital in Vancouver.

No abstract available

References

1. Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, et al. . Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012;308(8):804-11. - PubMed
1. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. . Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022;387(21):1923-34. Epub 2022 Nov 5. - PubMed
1. Hassanloo J, Béland-Bonenfant S, Paquette M, Baass A, Bernard S.. Prevalence, severity and management of hypertriglyceridemia-associated pancreatitis; a 7-year retrospective cohort study at Canadian quaternary care hospitals. J Clin Lipidol 2022;16(4):455-62. Epub 2022 May 21. - PubMed
1. Bodmer M, Brauchli YB, Krähenbühl S, Jick SS, Meier CR.. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009;302(18):2001-7. - PubMed
1. Coronary Drug Project Research Group . Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project. N Engl J Med 1977;296(21):1185-90. - PubMed